tHEORetically Speaking Podcast Por HealthEconomics.com arte de portada

tHEORetically Speaking

tHEORetically Speaking

De: HealthEconomics.com
Escúchala gratis

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

© 2026 tHEORetically Speaking
Ciencia Ciencias Biológicas
Episodios
  • Weekly News Roundup — PhRMA Leadership Transition, The ICHRA Shift, and MDUFA VI Preliminary Deal
    Apr 10 2026

    This week’s tHEORetically Speaking News Roundup covers Steve Ubl’s planned departure from PhRMA after a decade of navigating the industry through landmark legislative shifts, and the growing momentum of ICHRAs as employers move toward "defined contribution" healthcare models. We also break down the preliminary MDUFA VI agreement, which signals a major hiring push at the FDA and a new "America-First" fee structure for medtech.

    Tune in for this concise recap of these pivotal industry updates!

    Más Menos
    4 m
  • Weekly News Roundup — Medtech Mega Deals, EU Regulatory Delays, and Global Supply Chain Shock
    Mar 27 2026

    This week’s tHEORetically Speaking News Roundup covers Abbott’s $21 billion acquisition of Exact Sciences, signaling a major expansion in cancer diagnostics, and Boehringer Ingelheim’s concerns over Europe’s slowing regulatory timelines compared to the U.S. We also break down a global supply chain shock triggered by the Strait of Hormuz closure.

    Tune in for this concise recap of these pivotal industry updates!

    Más Menos
    3 m
  • Weekly News Roundup — Medicaid Maternal Care Expansion, Breakthrough Diabetes Data, and SMA Market Shakeups
    Mar 20 2026

    This week’s tHEORetically Speaking News Roundup covers Nadia Care’s $12M raise to expand Medicaid-focused maternal care, Eli Lilly’s breakthrough Phase 3 results for its triple agonist retatrutide in type 2 diabetes, and Roche’s decision to halt development of its SMA therapy—reshaping competition in the rare disease space.

    Tune in for this concise recap of the key developments shaping the HEOR, RWE, and market access landscape.

    Más Menos
    3 m
Todavía no hay opiniones